First Keytru­da biosim­i­lars move in­to clin­i­cal tri­als as Mer­ck push­es ahead with new for­mu­la­tion

At least three com­pa­nies have start­ed or are about to start tri­als of Keytru­da biosim­i­lars in what’s ex­pect­ed to cre­ate a wave of less ex­pen­sive com­peti­tors for Mer­ck’s block­buster im­muno-on­col­o­gy drug.

The biosim­i­lars are be­ing test­ed by Sam­sung Bioepis, San­doz and mAbx­ience Re­search, all with es­ti­mat­ed pri­ma­ry com­ple­tion dates in mid-2025, ac­cord­ing to Clin­i­cal­Tri­als.gov, the US gov­ern­ment data­base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER